JP7777596B2 - Cd38阻害剤としてのキノリン及びアザキノリン - Google Patents

Cd38阻害剤としてのキノリン及びアザキノリン

Info

Publication number
JP7777596B2
JP7777596B2 JP2023544674A JP2023544674A JP7777596B2 JP 7777596 B2 JP7777596 B2 JP 7777596B2 JP 2023544674 A JP2023544674 A JP 2023544674A JP 2023544674 A JP2023544674 A JP 2023544674A JP 7777596 B2 JP7777596 B2 JP 7777596B2
Authority
JP
Japan
Prior art keywords
alkyl
independently selected
cyclohexyl
amino
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023544674A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506814A (ja
Inventor
ダウニング,ジェニファー
ウェイン カンツ,ケビン
ビー シェンケル,ローリー
メアリー バズビンダー,メリッサ
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2024506814A publication Critical patent/JP2024506814A/ja
Priority to JP2025107301A priority Critical patent/JP2025160175A/ja
Application granted granted Critical
Publication of JP7777596B2 publication Critical patent/JP7777596B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023544674A 2021-01-29 2022-01-28 Cd38阻害剤としてのキノリン及びアザキノリン Active JP7777596B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025107301A JP2025160175A (ja) 2021-01-29 2025-06-25 Cd38阻害剤としてのキノリン及びアザキノリン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163143245P 2021-01-29 2021-01-29
US63/143,245 2021-01-29
PCT/US2022/014221 WO2022165114A1 (en) 2021-01-29 2022-01-28 Quinolines and azaquinolines as inhibitors of cd38

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025107301A Division JP2025160175A (ja) 2021-01-29 2025-06-25 Cd38阻害剤としてのキノリン及びアザキノリン

Publications (2)

Publication Number Publication Date
JP2024506814A JP2024506814A (ja) 2024-02-15
JP7777596B2 true JP7777596B2 (ja) 2025-11-28

Family

ID=80446310

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023544674A Active JP7777596B2 (ja) 2021-01-29 2022-01-28 Cd38阻害剤としてのキノリン及びアザキノリン
JP2025107301A Pending JP2025160175A (ja) 2021-01-29 2025-06-25 Cd38阻害剤としてのキノリン及びアザキノリン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025107301A Pending JP2025160175A (ja) 2021-01-29 2025-06-25 Cd38阻害剤としてのキノリン及びアザキノリン

Country Status (25)

Country Link
US (2) US11952377B2 (cg-RX-API-DMAC7.html)
EP (2) EP4674415A3 (cg-RX-API-DMAC7.html)
JP (2) JP7777596B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230141799A (cg-RX-API-DMAC7.html)
CN (1) CN117580829A (cg-RX-API-DMAC7.html)
AR (1) AR124718A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022212035A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023014898A2 (cg-RX-API-DMAC7.html)
CA (1) CA3208851A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023002163A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023009803A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230323A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000142A (cg-RX-API-DMAC7.html)
EC (1) ECSP23056223A (cg-RX-API-DMAC7.html)
ES (1) ES3042412T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251111T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072981T2 (cg-RX-API-DMAC7.html)
IL (1) IL304466A (cg-RX-API-DMAC7.html)
JO (1) JOP20230160A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023008701A (cg-RX-API-DMAC7.html)
PE (1) PE20232047A1 (cg-RX-API-DMAC7.html)
PL (1) PL4284511T3 (cg-RX-API-DMAC7.html)
RS (1) RS67253B1 (cg-RX-API-DMAC7.html)
TW (1) TW202241418A (cg-RX-API-DMAC7.html)
WO (1) WO2022165114A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11535621B2 (en) 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
EP4263524A1 (en) 2020-12-21 2023-10-25 Cytokinetics, Inc. Pyrazole derivatives useful as nampt modulators
CN117715897A (zh) 2021-04-30 2024-03-15 南京艾美斐生物医药科技有限公司 化合物及其作为cd38抑制剂的用途
WO2024217995A1 (en) 2023-04-20 2024-10-24 Syngenta Crop Protection Ag Pesticidally active dihydropyridinone derivatives
WO2026000074A1 (en) * 2024-06-25 2026-01-02 Welnx Company Inc. Use of cd38 inhibitors for reducing th2 inflammation
WO2026075971A1 (en) 2024-10-01 2026-04-09 Neolaia Inc. Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors
WO2026143058A1 (en) * 2024-12-23 2026-07-02 Neolaia Inc. Pyridopyrimidine compounds useful as cd38 inhibitors
WO2026143049A1 (en) * 2024-12-23 2026-07-02 Neolaia Inc. Aminoquinolinones useful as cd38 inhibitors
CN119775288B (zh) * 2024-12-31 2025-10-10 浙江工业大学 一种cd38抑制化合物及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016514147A (ja) 2013-03-14 2016-05-19 コンバージーン・リミテッド・ライアビリティ・カンパニーConvergene Llc ブロモドメイン含有タンパク質の阻害のための方法および組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2646020B1 (en) 2010-12-01 2016-09-21 Glaxosmithkline LLC Indoles
AU2012332297B2 (en) 2011-11-04 2016-01-07 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment
CN107428733A (zh) 2014-12-03 2017-12-01 葛兰素史克知识产权第二有限公司 Cd38抑制剂和治疗方法
WO2017053604A1 (en) 2015-09-23 2017-03-30 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
WO2018151830A1 (en) 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
EP3434692A1 (en) 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
US11535621B2 (en) 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
US20230025807A1 (en) 2019-10-30 2023-01-26 Mitobridge Inc. Cd38 inhibitors
KR20230051425A (ko) 2020-04-07 2023-04-18 미토브리지, 인크. Cd38 억제제

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016514147A (ja) 2013-03-14 2016-05-19 コンバージーン・リミテッド・ライアビリティ・カンパニーConvergene Llc ブロモドメイン含有タンパク質の阻害のための方法および組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAFFNER, C D. et al.,Discovery, Synthesis, and Biological Evaluation of Thiazoloquin(az)olin(on)es as Potent CD38 Inhibitors,Journal of Medicinal Chemistry,2015年,Vol.58,pp.3548-3571
SCULLY, S S. et al.,Synthesis and Evaluation of Thiazoloquinolinones with Linkers To Enable Targeting of CD38,ACS Medicinal Chemistry Letters,2017年,Vol.8,pp.196-200

Also Published As

Publication number Publication date
JP2025160175A (ja) 2025-10-22
TW202241418A (zh) 2022-11-01
ECSP23056223A (es) 2023-11-30
EP4674415A3 (en) 2026-03-04
CL2023002163A1 (es) 2024-01-05
PE20232047A1 (es) 2023-12-27
CA3208851A1 (en) 2022-08-04
JP2024506814A (ja) 2024-02-15
JOP20230160A1 (ar) 2023-07-20
US11952377B2 (en) 2024-04-09
EP4284511A1 (en) 2023-12-06
IL304466A (en) 2023-09-01
HUE072981T2 (hu) 2025-12-28
EP4674415A2 (en) 2026-01-07
US20240279224A1 (en) 2024-08-22
PL4284511T3 (pl) 2025-12-22
AU2022212035A1 (en) 2023-08-03
ES3042412T3 (en) 2025-11-20
RS67253B1 (sr) 2025-10-31
WO2022165114A1 (en) 2022-08-04
AU2022212035A9 (en) 2025-03-06
BR112023014898A2 (pt) 2023-10-31
KR20230141799A (ko) 2023-10-10
EP4284511B1 (en) 2025-07-16
HRP20251111T1 (hr) 2025-11-21
CN117580829A (zh) 2024-02-20
MX2023008701A (es) 2023-11-29
DOP2023000142A (es) 2023-08-31
AR124718A1 (es) 2023-04-26
CO2023009803A2 (es) 2023-10-09
CL2024001535A1 (es) 2024-11-04
US20220242862A1 (en) 2022-08-04
EP4284511C0 (en) 2025-07-16
CR20230323A (es) 2023-10-02

Similar Documents

Publication Publication Date Title
JP7721501B2 (ja) Cd38の阻害剤としてのヘテロ二環式アミド
EP4284511B1 (en) Azaquinolines as inhibitors of cd38
AU2016243939A1 (en) Heterocyclic compounds as LSD1 inhibitors
JP2015506362A (ja) キナーゼ阻害活性を有するベンズヒドロール−ピラゾール誘導体及びその使用
HK40129150A (en) Azaquinolines as inhibitors of cd38
EA049932B1 (ru) Хинолины и азахинолины в качестве ингибиторов cd38
EA048196B1 (ru) Гетеробициклические амиды как ингибиторы cd38
EA051811B1 (ru) Гетеробициклические амиды как ингибиторы cd38
HK40026838A (en) Heterocyclic compounds as lsd1 inhibitors
HK1249905B (en) Heterocyclic compounds as lsd1 inhibitors
HK1216316A1 (en) Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
HK1216316B (en) Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230818

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250626

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251021

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251117

R150 Certificate of patent or registration of utility model

Ref document number: 7777596

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02